Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed solid tumor, including primary brain tumor
• •* Progressive disease on standard therapy or for which no standard therapy exists
• •No symptomatic brain metastases
• •PATIENT CHARACTERISTICS:
• •Age:
• •1 to 21
• •Performance status:
• •Lansky 50-100% (age 10 and under)
• •Karnofsky 50-100% (over age 10)
• •Life expectancy:
• •At least 8 weeks
• •Hematopoietic:
• •Absolute neutrophil count greater than 1,000/mm3
• •Platelet count greater than 100,000/mm3
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL
• •ALT no greater than 2.5 times upper limit of normal
• •Renal:
• •Glomerular filtration rate at least 30 mL/min
• •Other:
• •No active infection
• •No serious uncontrolled medical disorder
• •No psychiatric disorder or other disorder that would preclude study
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 6 months since prior allogeneic bone marrow transplantation without evidence of acute or chronic graft versus host disease
• •At least 3 months since prior autologous bone marrow or peripheral blood stem cell transplantation
• •At least 4 weeks since prior immunotherapy and recovered
• •No concurrent immunotherapy
• •Chemotherapy:
• •No more than 3 prior chemotherapy regimens
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •No other concurrent chemotherapy
• •Endocrine therapy:
• •Concurrent hormone replacement therapy or oral contraceptives allowed
• •No other concurrent hormonal therapy
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy (including for brain metastases) and recovered
• •No concurrent radiotherapy
• •Surgery:
• •Not specified
• •Other:
• •No other concurrent investigational anticancer drugs
• •No other concurrent antitumor therapy
• •No concurrent anticonvulsants (e.g., phenytoin, phenobarbital, or carbamazepine) except gabapentin (Neurontin)